Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,488 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Dysfunction Clear all
Completed No phase listed Observational

Assessing Patient-Reported Experience of Care for Home Dialysis (ASPIRED)

NCT04435873
View directory record Official record
Conditions
Home Dialysis, End Stage Renal Disease
Interventions
Survey using "Your Home Dialysis Care Experience" tool.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
32
States / cities
Daly City, California • Emeryville, California • Folsom, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 4, 2026, 9:31 PM EDT
Active, not recruiting Not applicable Interventional

Improving Medical Decision Making for Older Patients With End Stage Renal Disease

NCT04347629
View directory record Official record
Conditions
Renal Disease, End Stage, Palliative Care, Decision Aids
Interventions
Advance Care Planning Video Decision Aid
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
65 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Boston, Massachusetts • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 4, 2026, 9:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

NCT05144971
View directory record Official record
Conditions
Diabete Mellitus, CKD, ESRD
Interventions
Glucose, Creatinine
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 4, 2026, 9:31 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
zigakibart
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Denver, Colorado • Acworth, Georgia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 4, 2026, 9:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485
View directory record Official record
Conditions
COVID-19
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 4, 2026, 9:31 PM EDT
Recruiting Phase 3 Interventional

Ultra-Low Contrast Angiography in AKI

NCT05906758
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Angiography
Procedure
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 4, 2026, 9:31 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

NCT04881448
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
collection of serum/capillary creatinine values
Diagnostic Test
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Huntsville, Alabama • Victorville, California • Bloomfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 4, 2026, 9:31 PM EDT
Terminated Phase 2Phase 3 Interventional

COOL RCN: Cooling to Prevent Radiocontrast Nephropathy

NCT00306306
View directory record Official record
Conditions
Renal Failure, Kidney Failure, Renal Insufficiency
Interventions
Reprieve Endovascular Temperature Therapy System
Device
Lead sponsor
Radiant Medical
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Not applicable Interventional

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

NCT00004285
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis, High dose, high flux hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 4, 2026, 9:31 PM EDT
Not listed Phase 3 Interventional

Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

NCT01357317
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Diet counseling, Phosphorus binder
Other · Drug
Lead sponsor
Salem Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 4, 2026, 9:31 PM EDT
Completed No phase listed Observational

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates

NCT02443389
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Minute to 2 Weeks
Enrollment
2,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

NCT01594424
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Tocilizumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 4, 2026, 9:31 PM EDT
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 4, 2026, 9:31 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

NCT03452189
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 4, 2026, 9:31 PM EDT
Not listed Not applicable Interventional

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

NCT05846113
View directory record Official record
Conditions
Kidney Diseases
Interventions
Renasight
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 4, 2026, 9:31 PM EDT
Active, not recruiting Phase 1 Interventional

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

NCT04540380
View directory record Official record
Conditions
Renal Failure
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 4, 2026, 9:31 PM EDT
Terminated Not applicable Interventional Results available

Diuretic/Cool Dialysate Trial

NCT02593526
View directory record Official record
Conditions
Chronic Kidney Insufficiency
Interventions
Bumetanide, Cool Dialysate
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 4, 2026, 9:31 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

NCT00608491
View directory record Official record
Conditions
Heart Failure
Interventions
Stepped pharmacologic care, Ultrafiltration
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 4, 2026, 9:31 PM EDT